Early Implementation of QbD in Biopharmaceutical Development: A Practical Example

In drug development, the “onus” of the low R&D efficiency has been put traditionally onto the drug discovery process (i.e., finding the right target or “binding” functionality). Here, we show that manufacturing is not only a central component of product success, but also that, by integrating manufacturing and discovery activities in a “holistic” interpretation of QbD methodologies, we could expect to increase the efficiency of the drug discovery process as a whole. In this new context, early risk assessment, using developability methodologies and computational methods in particular, can assist in reducing risks during development in a cost-effective way. We define specific areas of risk and how they can impact product quality in a broad sense, including essential aspects such as product efficacy and patient safety. Emerging industry practices around developability are introduced, including some specific examples of applications to biotherapeutics. Furthermore, we suggest some potential workflows to illustrate how developability strategies can be introduced in practical terms during early drug development in order to mitigate risks, reduce drug attrition and ultimately increase the robustness of the biopharmaceutical supply chain. Finally, we also discuss how the implementation of such methodologies could accelerate the access of new therapeutic treatments to patients in the clinic.

[1]  I. Macdougall,et al.  Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. , 2012, Kidney international.

[2]  Marie-Claude Djidja,et al.  Aggregation of Human Recombinant Monoclonal Antibodies Influences the Capacity of Dendritic Cells to Stimulate Adaptive T-Cell Responses In Vitro , 2014, PloS one.

[3]  G. Kuchel,et al.  ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.

[4]  Yi Li,et al.  High throughput formulation screening for global aggregation behaviors of three monoclonal antibodies. , 2011, Journal of pharmaceutical sciences.

[5]  T. Boone,et al.  Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. , 2007, Clinical immunology.

[6]  Steven J Shire,et al.  Formulation and manufacturability of biologics. , 2009, Current opinion in biotechnology.

[7]  Khaled Bouri,et al.  Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012. , 2014, JAMA.

[8]  Simona Jevševar,et al.  PEGylation of therapeutic proteins , 2010, Biotechnology journal.

[9]  A. Beck,et al.  Identification of B- and T-Cell Epitopes of BB, a Carrier Protein Derived from the G Protein of Streptococcus Strain G148 , 2003, Clinical Diagnostic Laboratory Immunology.

[10]  Olga Obrezanova,et al.  Aggregation risk prediction for antibodies and its application to biotherapeutic development , 2015, mAbs.

[11]  Fredrik Y Frejd,et al.  Half‐Life Extension by Binding to Albumin through an Albumin Binding Domain , 2012 .

[12]  David C. Lowe,et al.  Application of Biophysics to the Early Developability Assessment of Therapeutic Candidates and Its Application to Enhance Developability Properties , 2013 .

[13]  W. Xu,et al.  Developability studies before initiation of process development , 2013, mAbs.

[14]  M. Pallardy,et al.  Primate testing of TGN1412: right target, wrong cell , 2010, British journal of pharmacology.

[15]  C. Dobson,et al.  Rational design of aggregation-resistant bioactive peptides: reengineering human calcitonin. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Edmundson,et al.  Comparison of the three‐dimensional structures of a humanized and a chimeric Fab of an anti‐γ‐interferon antibody , 1999, Journal of molecular recognition : JMR.

[17]  Janet Clarke Mechanisms of adverse drug reactions to biologics. , 2010, Handbook of experimental pharmacology.

[18]  Quynh-Thu Le,et al.  Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. , 2008, The New England journal of medicine.

[19]  M. Wadhwa,et al.  Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy. , 2011, Journal of immunological methods.

[20]  Nicki Panoskaltsis,et al.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. , 2006, The New England journal of medicine.

[21]  G. Gilliland,et al.  Structure-based engineering of a monoclonal antibody for improved solubility. , 2010, Protein engineering, design & selection : PEDS.

[22]  H. Attarwala,et al.  TGN1412: From Discovery to Disaster , 2010, Journal of young pharmacists : JYP.

[23]  D. Rudmann,et al.  High Molecular Weight Polyethylene Glycol Cellular Distribution and PEG-associated Cytoplasmic Vacuolation Is Molecular Weight Dependent and Does Not Require Conjugation to Proteins , 2013, Toxicologic pathology.

[24]  W. Jiskoot,et al.  Erythropoietin-Associated PRCA: Still an Unsolved Mystery , 2006, Journal of immunotoxicology.

[25]  T. Igawa,et al.  Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity , 2013, PloS one.

[26]  Vladimir I Razinkov,et al.  Native-state solubility and transfer free energy as predictive tools for selecting excipients to include in protein formulation development studies. , 2012, Journal of pharmaceutical sciences.

[27]  Steven Kozlowski,et al.  Current and future issues in the manufacturing and development of monoclonal antibodies. , 2006, Advanced drug delivery reviews.

[28]  Robert Fischer,et al.  Tungsten-Induced Denaturation and Aggregation of Epoetin Alfa During Primary Packaging as a Cause of Immunogenicity , 2011, Pharmaceutical Research.

[29]  A. Rosenberg,et al.  A risk-based approach to immunogenicity concerns of therapeutic protein product, Pat III , 2004 .

[30]  A. Buisman,et al.  Optimization of a human IgG B-cell ELISpot assay for the analysis of vaccine-induced B-cell responses. , 2013, Journal of immunological methods.

[31]  L. Abrahmsén,et al.  Engineering of a femtomolar affinity binding protein to human serum albumin. , 2008, Protein engineering, design & selection : PEDS.

[32]  Thomas Singer,et al.  The safety and side effects of monoclonal antibodies , 2010, Nature Reviews Drug Discovery.

[33]  R Seitz,et al.  Taking immunogenicity assessment of therapeutic proteins to the next level. , 2011, Biologicals : journal of the International Association of Biological Standardization.

[34]  Sandeep Kumar,et al.  Identification and Impact of Aggregation‐Prone Regions in Proteins and Therapeutic Monoclonal Antibodies , 2010 .

[35]  N. Robinson,et al.  Molecular clocks. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Abuchowski,et al.  The clinical efficacy of poly(ethylene glycol)-modified proteins , 1990 .

[37]  A. Rathore,et al.  Quality by design for biopharmaceuticals , 2009, Nature Biotechnology.

[38]  Gary Walsh,et al.  Post-translational modifications of protein biopharmaceuticals. , 2009, Drug discovery today.

[39]  W. Stemmer,et al.  GLP2-2G-XTEN: A Pharmaceutical Protein with Improved Serum Half-Life and Efficacy in a Rat Crohn’s Disease Model , 2012, PloS one.

[40]  P. Parren,et al.  Immunogenicity screening in protein drug development , 2007, Expert opinion on biological therapy.

[41]  F. Curtin,et al.  Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein , 2015, mAbs.

[42]  Steven J Shire,et al.  Challenges in the development of high protein concentration formulations. , 2004, Journal of pharmaceutical sciences.

[43]  Andrew J Racher,et al.  Antibody production. , 2006, Advanced drug delivery reviews.

[44]  Jennifer R Litowski,et al.  High-throughput dynamic light scattering method for measuring viscosity of concentrated protein solutions. , 2010, Analytical biochemistry.

[45]  Fred Jacobson,et al.  Protein aggregation and bioprocessing , 2006, The AAPS Journal.

[46]  Karsten Mäder,et al.  Assessment of net charge and protein-protein interactions of different monoclonal antibodies. , 2011, Journal of pharmaceutical sciences.

[47]  S. A. Marshall,et al.  Minimizing the immunogenicity of protein therapeutics. , 2004, Drug discovery today.

[48]  Noel Smith,et al.  Developability Assessment Workflows to De-Risk Biopharmaceutical Development , 2015 .

[49]  W. Stemmer,et al.  Correction: GLP2-2G-XTEN: A Pharmaceutical Protein with Improved Serum Half-Life and Efficacy in a Rat Crohn’s Disease Model , 2013, PloS one.

[50]  Florian Dismer,et al.  3D structure-based protein retention prediction for ion-exchange chromatography. , 2010, Journal of chromatography. A.

[51]  M. Bardor,et al.  Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins , 2012, Biotechnology journal.

[52]  Michele Vendruscolo,et al.  Prediction of "aggregation-prone" and "aggregation-susceptible" regions in proteins associated with neurodegenerative diseases. , 2005, Journal of molecular biology.

[53]  Sandeep Kumar,et al.  Potential Aggregation-Prone Regions in Complementarity-Determining Regions of Antibodies and Their Contribution Towards Antigen Recognition: A Computational Analysis , 2010, Pharmaceutical Research.

[54]  E. Kandel,et al.  Proceedings of the National Academy of Sciences of the United States of America. Annual subject and author indexes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[55]  J. Zurdo,et al.  Developability assessment as an early de-risking tool for biopharmaceutical development , 2013 .

[56]  A. D. Nielsen,et al.  Viscosity of high concentration protein formulations of monoclonal antibodies of the IgG1 and IgG4 subclass - prediction of viscosity through protein-protein interaction measurements. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[57]  S. Singh,et al.  An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. , 2010, Journal of pharmaceutical sciences.

[58]  Hongcheng Liu,et al.  Heterogeneity of monoclonal antibodies. , 2008, Journal of pharmaceutical sciences.

[59]  William R. Strohl,et al.  Therapeutic antibody engineering , 2012 .

[60]  Patrick Garidel,et al.  Viscosity measurements of antibody solutions by photon correlation spectroscopy: an indirect approach – limitations and applicability for high-concentration liquid protein solutions , 2013, Pharmaceutical development and technology.

[61]  A. Rosenberg,et al.  Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.

[62]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[63]  C. Breneman,et al.  Prediction of protein retention in ion-exchange systems using molecular descriptors obtained from crystal structure. , 2001, Analytical chemistry.

[64]  Brian M. Murphy,et al.  Stability of Protein Pharmaceuticals: An Update , 2010, Pharmaceutical Research.

[65]  Deborah S. Goldberg,et al.  Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability. , 2011, Journal of pharmaceutical sciences.

[66]  William F Weiss,et al.  Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. , 2009, Journal of pharmaceutical sciences.

[67]  A. Bircher,et al.  Adverse drug reactions to biologics , 2010, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[68]  M. Ravnborg [Natalizumab (Tysabri)]. , 2007, Ugeskrift for laeger.

[69]  R. Farrell,et al.  Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis , 2014 .

[70]  L. DeLucas,et al.  High-Throughput Self-Interaction Chromatography: Applications in Protein Formulation Prediction , 2009, Pharmaceutical Research.

[71]  J. Curling Affinity chromatography from textile dyes to synthetic ligands by design. Part 2 , 2004 .

[72]  M. Kahook,et al.  Sustained Intraocular Pressure Elevation After Intravitreal Injection of Bevacizumab and Ranibizumab Associated with Trabeculitis , 2010, The open ophthalmology journal.

[73]  A. Rosenberg,et al.  A risk-based approach to immunogenicity concerns of therapeutic protein products: Part 2. Considering host-specific and product-specific factors impacting immunogenicity , 2004 .

[74]  Michele Vendruscolo,et al.  Prediction of aggregation-prone regions in structured proteins. , 2008, Journal of molecular biology.

[75]  Bernhardt L Trout,et al.  Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. , 2012, Journal of pharmaceutical sciences.

[76]  Leslie R Evans,et al.  Albumin as a versatile platform for drug half-life extension. , 2013, Biochimica et biophysica acta.

[77]  D. Grainger Controlled-release and local delivery of therapeutic antibodies , 2004, Expert opinion on biological therapy.

[78]  Tilman Schlothauer,et al.  Assessment of chemical modifications of sites in the CDRs of recombinant antibodies , 2014, mAbs.

[79]  D. James,et al.  Predicting the expression of recombinant monoclonal antibodies in Chinese hamster ovary cells based on sequence features of the CDR3 domain , 2014, Biotechnology progress.

[80]  Quynh-Thu Le,et al.  Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose , 2008 .

[81]  M. Wadhwa,et al.  “Cytokine Storm” in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics , 2007, The Journal of Immunology.

[82]  S. Joshi,et al.  Multidimensional methods for the formulation of biopharmaceuticals and vaccines. , 2011, Journal of pharmaceutical sciences.

[83]  Amedeo Caflisch,et al.  Computational models for the prediction of polypeptide aggregation propensity. , 2006, Current opinion in chemical biology.

[84]  Sandeep Yadav,et al.  Weak interactions govern the viscosity of concentrated antibody solutions: high-throughput analysis using the diffusion interaction parameter. , 2012, Biophysical journal.

[85]  A. Serone,et al.  Autoantibodies to Variable Heavy (VH) Chain Ig Sequences in Humans Impact the Safety and Clinical Pharmacology of a VH Domain Antibody Antagonist of TNF-α Receptor 1 , 2013, Journal of Clinical Immunology.

[86]  K. Ishigaki,et al.  Cardiopulmonary Arrest After Severe Anaphylactic Reaction to Second Infusion of Infliximab in a Patient with Ankylosing Spondylitis , 2011, The Journal of Rheumatology.

[87]  B. Kabakoff,et al.  Identification of multiple sources of charge heterogeneity in a recombinant antibody. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[88]  Herbert J Meiselman,et al.  Antibody against poly(ethylene glycol) adversely affects PEG‐asparaginase therapy in acute lymphoblastic leukemia patients , 2007, Cancer.

[89]  María Vázquez-Rey,et al.  Aggregates in monoclonal antibody manufacturing processes , 2011, Biotechnology and bioengineering.

[90]  Michele Vendruscolo,et al.  Theoretical approaches to protein aggregation. , 2006, Protein and peptide letters.

[91]  Huub Schellekens,et al.  Structure-Immunogenicity Relationships of Therapeutic Proteins , 2004, Pharmaceutical Research.

[92]  Vibha Jawa,et al.  T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. , 2013, Clinical immunology.

[93]  E. Hoffenberg,et al.  A Home Infliximab Infusion Program , 2005, Journal of pediatric gastroenterology and nutrition.

[94]  H. Mach,et al.  High-dose monoclonal antibodies via the subcutaneous route: challenges and technical solutions, an industry perspective. , 2012, Therapeutic delivery.

[95]  Huijuan Li,et al.  Pharmacological significance of glycosylation in therapeutic proteins. , 2009, Current opinion in biotechnology.

[96]  J. Arrowsmith,et al.  Trial Watch: Phase II and Phase III attrition rates 2011–2012 , 2013, Nature Reviews Drug Discovery.

[97]  Bernhardt L Trout,et al.  Computational methods to predict therapeutic protein aggregation. , 2012, Methods in molecular biology.

[98]  R. Minter,et al.  Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression , 2013, mAbs.

[99]  T. Singer,et al.  A simple whole blood bioassay detects cytokine responses to anti-CD28SA and anti-CD52 antibodies. , 2013, Journal of pharmacological and toxicological methods.

[100]  Matthew J. Frigault,et al.  Predicting cytokine storms: it's about density. , 2011, Blood.